科研日报 2025-11-14

Page content

📅 Daily Report - 2025-11-14

今日筛选出 84 条内容,来自 4 个来源

Powered by 科研普拉斯 & Claude

🤖 今日AI智能总结

📰 公众号

今日焦点: 首次发现癌细胞利用“痛感神经”远程操控免疫系统,阻断此通路可实现抗癌与镇痛“双赢”;AI技术在单细胞数据解释方面取得突破性进展。

主要方向

  • 肿瘤免疫微环境调控:识别并靶向特定细胞亚型(如HLA-DR+肿瘤细胞、PLAUR+中性粒细胞、CD177+中性粒细胞、CTCF+TAN、IL-33+内皮细胞、MMP11+成纤维细胞)以改善免疫治疗疗效或减轻疾病损伤。
  • 肠道-肝脏轴与代谢调控:解析肠道-肝脏轴的代谢调控机制,以及代谢物对巨噬细胞极化和肿瘤的影响。
  • 单细胞与空间组学应用:探索单细胞空间转录组学在脑和肺研究中的平台比较;空间三组学绘制大脑发育与神经炎症图谱。

技术亮点

  • 多组学结合:运用单细胞、空间组学、干湿结合、机器学习等多种技术手段进行深度分析。
  • AI辅助分析:AI技术在单细胞数据解释方面展现出巨大潜力。

🧬 数据前沿

今日焦点: CDK4/6抑制剂在乳腺癌治疗中展现出重塑免疫肽段组、诱导持久生长停滞的潜力;同时,KRAS和CDK4的联合靶向治疗在胰腺癌中显示出协同效应。

主要方向

  • 癌症免疫逃逸机制:如6PGD抑制与天然免疫应答的关联,以及PD-L1和miR-27a-3p协同重塑T细胞治疗炎症性肠病。
  • 信号通路与耐药性:Oxr1失调在慢性髓系白血病TKI耐药中的作用;USP13稳定SOX9促进脂肪肝及肝癌干细胞表型。
  • 表观遗传调控:DNA甲基化编辑在体内研究;Sp8和Brachyury在胚胎干细胞分化中的结合谱。

技术亮点

  • 整合多组学数据(全外显子组测序+scRNA-seq)揭示特定癌症样本特征。
  • 空间转录组学分析衰老卵巢。

🔬 期刊文章

今日焦点: 揭示了休眠癌细胞(DCC)的机制,为克服癌症转移和治疗耐药性提供了新视角。

主要方向

  • 探索Tetraspanin 13(TSPAN13)在乳腺癌免疫逃逸中的作用,及其通过MHC-I降解增强免疫抑制的机制。
  • 研究TET2失活在造血系统中的作用,以及其如何增强免疫检查点阻断(ICB)的疗效。
  • 关注EGFR突变非小细胞肺癌(NSCLC)中EGFR TKI耐药的机制及新型治疗策略。

技术亮点

  • 整合基因组、表型和活细胞成像分析,用于解码癌症休眠。
  • 动态肿瘤免疫表型分析,评估新辅助化疗联合曲妥珠单抗治疗HER2阳性乳腺癌的疗效。

🧪 博客更新

今日焦点: AI驱动的多模态学习工具CellWhisperer实现基于自然语言的单细胞基因表达数据交互探索,革新生物数据分析方式。

主要方向

  • 利用AI和RNA测序数据,实现单细胞基因表达的自然语言交互式探索。
  • 整合功能性药物测试、RNA测序与AI,为癌症患者提供个性化治疗洞察。
  • GLP-1类药物(如Ozempic、Wegovy)可能显著降低结直肠癌患者死亡率。
  • 开发新型智能药物,靶向并破坏癌细胞依赖的特定RNA结构,触发细胞自毁。

技术亮点

  • 基于AI的多模态学习,实现生物数据(RNA测序)与自然语言的融合。
  • 智能药物设计,能识别并作用于RNA的特定折叠结构。

📚 分类浏览

📰 公众号 (38条)

详细内容(前10条)

1.Early View | 南方医科大学余光创教授团队 两种测序平台在小鼠脑和肺单细胞空间转录组学研究中的比较

  • ✍️ 作者:YuLabSMU
  • 🏷️ 关键词:测序、单细胞、空间转录组、空间组学、转录组
  • 📝 描述:Early View | 南方医科大学余光创教授团队 Illumina NovaSeq 6000 与 GeneMind SURFSeq 5000平台在小鼠脑和肺单细胞空间转录组学研究中的比较
  • 🔗 查看原文

2.最新14+生信,通过单细胞分析识别HLA-DR +肿瘤细胞,并分析其对 CD8+T 细胞及预后的影响,思路新颖!

  • ✍️ 作者:生信小课堂
  • 🏷️ 关键词:肿瘤、单细胞、生信、通路
  • 📝 描述:点击查看详情
  • 🔗 查看原文

3.最新14+生信,单细胞识别PLAUR+中性粒细胞塑造免疫抑制微环境,抑制PLAUR 增强抗 PD1 疗效。高分文章经典思路!

  • ✍️ 作者:生信小课堂
  • 🏷️ 关键词:免疫、免疫微环境、单细胞、生信
  • 📝 描述:点击查看详情
  • 🔗 查看原文

4.10.6分非肿瘤干湿结合生信,靶向 CD177 + 中性粒细胞减轻缺血再灌注损伤。适合动物建模测序思路!

  • ✍️ 作者:生信小课堂
  • 🏷️ 关键词:肿瘤、测序、生信
  • 📝 描述:点击查看详情
  • 🔗 查看原文

5.最新10分生信,单细胞+空转多组学进行中性粒细胞亚型分析,识别 CTCF+TAN,靶向CTCF改善免疫治疗疗效!

  • ✍️ 作者:生信小课堂
  • 🏷️ 关键词:免疫、单细胞、生信
  • 📝 描述:点击查看详情
  • 🔗 查看原文

6.《Cell》:癌细胞竟用“痛感神经”远程操控免疫系统!阻断此通路,可实现抗癌与镇痛“双赢”

  • ✍️ 作者:生信人
  • 🏷️ 关键词:免疫、神经、通路
  • 📝 描述:在肿瘤免疫学领域,为什么强大的免疫系统会“失灵”,任由癌细胞生长?
  • 🔗 查看原文

7. 最新7.5分生信,多组学结合机器学习筛选肥胖相关的关键基因并验证,非肿瘤经典思路!

  • ✍️ 作者:东晓生物
  • 🏷️ 关键词:肿瘤、生信
  • 🔗 查看原文

8. 基因注释信息整合有困难?找GenomicFeatures包帮你搞定所有基因组注释难题!

  • ✍️ 作者:云生信
  • 🏷️ 关键词:基因组、R包
  • 🔗 查看原文

9. 刚刚发表的8.9分生信,除了识别某基因阳性细胞,识别某通路/表型阳性细胞也是发文的好思路!

  • ✍️ 作者:生信小课堂
  • 🏷️ 关键词:生信、通路
  • 📝 描述:点击查看详情
  • 🔗 查看原文

10. 33+生信, 识别从癌前病变到肿瘤不同恶性程度相关的细胞亚型,针对IL-33+内皮细胞促进疾病进展进行实验验证!

  • ✍️ 作者:生信小课堂
  • 🏷️ 关键词:肿瘤、生信
  • 📝 描述:点击查看详情
  • 🔗 查看原文

💡 该来源还有 28 条内容,详见 文末

🧬 数据前沿 (35条)

详细内容(前10条)

1.GSE278674 阻断 6PGD 可限制癌症中由先天免疫反应驱动的免疫抑制

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:cancer、immune、regex:immuno(logy|therapy|suppression)
  • 📝 描述:Contributors : Saeed Daneshmandi ; Eduardo C Gomez ; Jianmin Wang ; Hemn MohammadpourSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe pentose phosphate pathway (PPP) has always been relegated to the background of cellular metabolism, but our research identifies its unique and provocative influence on cell function, specifically in myeloid-derived suppressor cells (MDSCs). We’ve uncovered that 6-phosphogluconate dehydrogenase (6PGD), a rate limiting enzyme in this pathway, is not just a metabolic enzyme but a crucial determinant of MDSC behavior. While the IL-6/STAT3 axis propels 6PGD activity, it also empowers MDSCs to exert their immune-suppressive prowess. When we disrupt 6PGD – either through genetic knockout or pharmacological inhibition – an astonishing transformation occurs. The accumulation of 6-phosphogluconate (6PG) sets off a cascade involving JNK1-IRS-1 interaction and PI3K-AKT-pDRP1 signaling pathway, triggering mitochondrial fragmentation and dismantling oxidative phosphorylation (OXPHOS). This change in metabolism doesn’t just disrupt MDSC function; it transforms it stimulatory, leading to a strong anti-tumor response and making anti-PD1 therapies much more effective. Our results suggest we need to completely rethink the role of the PPP in cell function, with 6PGD emerging as a key target that could change the future of cancer immunotherapy.
  • 🔗 查看原文

2.GSE254498 整合全外显子组测序和单细胞RNA测序揭示了VHL病背景下发生的一例透明细胞肾细胞癌样本的特征

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:carcinoma、sequencing、scRNA
  • 📝 描述:Contributors : Wenhao Lu ; Tingwei Jin ; Xiaoxiang Yu ; Yixuan Liu ; Shengzhu Huang ; Zheng Wen ; Cheng Su ; Yu Ye ; Ziyan Huang ; Zengnan Mo ; Zhenyuan YuSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensClear cell renal cell carcinoma (ccRCC) arising in the setting of von Hippel–Lindau (VHL) disease is a rare type of kidney cancer and features VHL germline mutation. This type of ccRCC is rarely characterised at the single-cell level. In this work, whole-exome sequencing and single-cell RNA sequencing (scRNA-seq) were conducted on one ccRCC sample with VHL disease. Integrating scRNA-seq and whole-exome sequencing data by the Seurat package, we determined the relationship between single-cell transcriptome features and gene mutations. Immunohistochemistry and immunofluorescence were performed on one VHL germline mutation ccRCC and six non-VHL germline mutation ccRCC samples. We revealed the gene expression characteristics of ccRCC with VHL germline mutation. The frameshift mutations in OBP2A and BCR1, and the elevated expression of COX7A1 were most specific characteristics of ccRCC tumor cells with VHL mutation. And the extensive infiltration of exhausted T cells was the characteristic of tumor microenvironment. In addition, we discovered the relationship between genetic mutations and immune checkpoints. This work highlights the single-cell transcriptome and DNA-level information of this rare ccRCC and will provide more genetic insights and references into this rare disease.
  • 🔗 查看原文

3. GSE281956 氧化抵抗 1 (Oxr1) 失调促进慢性粒细胞白血病中的 TKI 耐药性和急变期。

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:leukemia、resistance
  • 📝 描述:Series Type : Genome variation profiling by high throughput sequencing ; Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiens ; Mus musculusThis SuperSeries is composed of the SubSeries listed below.
  • 🔗 查看原文

4. GSE281955 氧化抵抗 1 (Oxr1) 失调促进慢性粒细胞白血病中的 TKI 耐药性和急变期 [数据集 3]

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:leukemia、resistance
  • 📝 描述:Contributors : Weiqi Huang ; Elizabeth Eklund ; Priyam PatelSeries Type : OtherOrganism : Mus musculusTo unravel the intricate interplay among Oxr1, ROS-induced genetic changes, and dynamics influencing TKI resistance and CML progression
  • 🔗 查看原文

5. GSE281954 氧化抵抗 1 (Oxr1) 失调促进慢性粒细胞白血病中的 TKI 耐药性和急变期 [数据集 2]

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:leukemia、resistance
  • 📝 描述:Contributors : Weiqi Huang ; Elizabeth Eklund ; Priyam PatelSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo unravel the intricate interplay among Oxr1, ROS-induced genetic changes, and dynamics influencing TKI resistance and CML progression
  • 🔗 查看原文

6. GSE281856 氧化抵抗 1 (Oxr1) 失调促进慢性粒细胞白血病中的 TKI 耐药性和急变期 [数据集 1]

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:leukemia、resistance
  • 📝 描述:Contributors : Weiqi Huang ; Elizabeth Eklund ; Priyam PatelSeries Type : Genome variation profiling by high throughput sequencingOrganism : Mus musculusTo unravel the intricate interplay among Oxr1, ROS-induced genetic changes, and dynamics influencing TKI resistance and CML progression
  • 🔗 查看原文

7. GSE280073 体内DNA甲基化编辑[ChIP-Seq]

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:ChIP-seq、methylation
  • 📝 描述:Contributors : Richard Pan ; Luis Flores ; X Shawn LiuSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusDNA methylation is an epigenetic mechanism essential for orchestrating gene expression. Precise editing of DNA methylation has emerged as a new method to dissect its biological function in a DNA sequence specific manner with great potential to treat human diseases. However, applications of DNA methylation editing are largely in vitro. An experimental system to systematically investigate in vivo DNA methylation editing is needed to reveal its full therapeutic potential. We generated two transgenic mouse lines carrying an inducible dCas9-Dnmt3a or dCas9-Tet1 editor to enable cell-type specific methylation editing in vivo. We demonstrated that targeted methylation of the Psck9 promoter in the liver of dCas9-Dnmt3a mice reduced Psck9 expression and lowered plasma low-density lipoprotein cholesterol level to reduce the risk for cardiovascular diseases. Targeted demethylation of the Mecp2 promoter by dCas9-Tet1 reactivated Mecp2 expression from the inactive X chromosome in the brain of Mecp2 heterozygous Rett syndrome mice, suggesting a promising therapeutic approach for Rett syndrome and other X-linked diseases. Genome-wide sequencing analysis showed no detectable off-target at the transcriptional level in the methylation edited mice. These results demonstrate the feasibility and versatility of methylation editing in vivo, to explore DNA methylation in normal physiology and develop treatments for human diseases.
  • 🔗 查看原文

8. GSE280072 体内DNA甲基化编辑[RNA-Seq]

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:RNA-seq、methylation
  • 📝 描述:Contributors : Richard Pan ; X Shawn LiuSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDNA methylation is an epigenetic mechanism essential for orchestrating gene expression. Precise editing of DNA methylation has emerged as a new method to dissect its biological function in a DNA sequence specific manner with great potential to treat human diseases. However, applications of DNA methylation editing are largely in vitro. An experimental system to systematically investigate in vivo DNA methylation editing is needed to reveal its full therapeutic potential. We generated two transgenic mouse lines carrying an inducible dCas9-Dnmt3a or dCas9-Tet1 editor to enable cell-type specific methylation editing in vivo. We demonstrated that targeted methylation of the Psck9 promoter in the liver of dCas9-Dnmt3a mice reduced Psck9 expression and lowered plasma low-density lipoprotein cholesterol level to reduce the risk for cardiovascular diseases. Targeted demethylation of the Mecp2 promoter by dCas9-Tet1 reactivated Mecp2 expression from the inactive X chromosome in the brain of Mecp2 heterozygous Rett syndrome mice, suggesting a promising therapeutic approach for Rett syndrome and other X-linked diseases. Genome-wide sequencing analysis showed no detectable off-target at the transcriptional level in the methylation edited mice. These results demonstrate the feasibility and versatility of methylation editing in vivo, to explore DNA methylation in normal physiology and develop treatments for human diseases.
  • 🔗 查看原文

9. GSE274072 USP13 稳定 SOX9 以促进代谢功能障碍相关的脂肪肝疾病和肝癌干细胞表型

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:cancer、metabolic
  • 📝 描述:Contributors : Shao Na ; Zhang Lin ; Tan Xu ; Xiang Jingyi ; Xi Lei ; Idris Muhammad ; Shen Gufang ; Zhou Lu ; Ni Yuanshu ; Zhang Qiongyi ; Xu Feng ; Liu ChungangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDeregulation of SOX9 has been linked with metabolic diseases, self-renewal and cancer. SOX9, a master regulator of cell growth, can be regulated by a diverse set of Post-Translational Modifications (PTMs), including ubiquitylation. This study aims to elucidate the mechanisms that govern SOX9 protein stability that is mediated by the ubiquitin-proteasome system. Following a screen of the deubiquitinase library, SOX9 protein abundance was found to be regulated by ubiquitin-specific peptidase 13 (USP13) which deubiquitylates SOX9 and inhibits its protein degradation. Additionally, USP13 attenuates FBXW7- and KEAP1-mediated ubiquitination and degradation of SOX9 by directly binding to the SOX9 K2 domain, which contains a critical ubiquitination residue-K249. Genetic deletion or pharmacological inhibition of USP13 markedly decreases the metabolic dysfunction-associated fatty liver disease (MAFLD) development, the stemness capacity of liver cancer cells and enhances its chemo-sensitivity. Overexpression of exogenous SOX9 in USP13 deficient cells restored liver cancer cells self-renewal capacity and tumorigenesis. Clinical analyses revealed that the USP13-SOX9 axis is associated with poor prognosis in human hepatocellular carcinoma (HCC) patients. Therefore, pharmacological interventions targeting USP13 may have therapeutic potential for the treatment of HCC and MAFLD prevalent diseases.
  • 🔗 查看原文

10. GSE267315 衰老人类卵巢的空间转录组特征

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:aging、spatial
  • 📝 描述:Contributors : Meiling Zhang ; Fanghao Guo ; Qing Zhang ; Qianhui Hu ; Di Sun ; Yongjian Ma ; Yanquan Li ; Mengxi Guo ; Haixia Ding ; Ying Guo ; Baicai Yang ; Songmao Li ; Ningxia Sun ; Yuxuan Zheng ; Wen LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensOvarian aging is a complex process that compromises fertility and elevates the risk of reproductive disorders. To elucidate its spatiotemporal dynamics, we integrated single-nucleus RNA sequencing and spatial transcriptomics to construct a comprehensive aging atlas of 12 human ovarian tissues spanning ages 12-54. Our analysis revealed aging-associated transcriptomic shifts, including impaired mitochondrial oxidative phosphorylation and reproductive structure development in aged human ovaries. We identified a novel endothelial cell (EDC) subtype, CLDN5⁺ blood EDCs, which exhibited unique functional specialization as (semi-professional) antigen-presenting cells. In contrast to other cell types that lost cell identity during aging, CLDN5⁺ blood EDCs displayed transcriptomic sensitivity to aging, characterized by enhanced antigen-presenting capabilities, and heightened inflammatory activity. Spatial mapping further uncovered immunoglobulin-expressing cell (IGHG1+/IGKC+) accumulation in the ovarian periphery, correlating with advancing age. Critically, aging disrupted global cellular connectivity while amplifying the DLK1:NOTCH3 axis between theca cells and CLDN5⁺ blood EDCs, which may contribute to the dysregulation of ovarian functions. The progressively upregulation of DLK1 indicates it as a robust biomarker of ovarian aging. This study significantly enhances our comprehension of the underlying mechanisms of human ovarian aging and concurrently pinpoints potential therapeutic avenues for addressing related disorders.
  • 🔗 查看原文

💡 该来源还有 25 条内容,详见 文末

🔬 期刊文章 (7条)

详细内容(全部7条)

1. 老龄化癌症幸存者人群的心血管风险。

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:癌症、心血管
  • 📝 描述:Secret hovertext:
  • 🔗 查看原文

2. 解码癌症休眠:整合基因组、表型和活细胞成像分析,揭示隐藏的癌细胞库

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:癌症、基因组
  • 📝 描述:Secret hovertext: 转移是癌症治疗中最困难的障碍之一,是许多癌症相关死亡的原因。了解驱动疾病进展的机制对于改善患者预后和制定更有效的治疗策略至关重要。这种现象似乎是由休眠癌细胞 (DCC) 引起的,这些细胞可以长时间持续未被发现,进入非增殖、冬眠样状态,从而对传统疗法产生耐药性并促进免疫逃避。由于 DCC 作为稀有且能量受限的人群,加上当前医学成像的局限性,它们往往逃避早期发现,阻碍了及时干预和有效的临床管理。因此,迫切需要开发高分辨率检测系统并识别特定的 DCC 靶向生物标志物。在这里,报告了对当前对 DCC 的理解的全面概述,重点关注其识别和跟踪实验策略的最新进展,以及目前正在进行的旨在靶向这些难以捉摸的细胞的临床研究方法。
  • 🔗 查看原文

3. 新辅助化疗联合曲妥珠单抗治疗 HER2 阳性乳腺癌的动态肿瘤免疫表型前景

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:肿瘤、免疫
  • 📝 描述:Secret hovertext: 对于 HER2 阳性乳腺癌(BC),达到病理完全缓解(pCR)的患者预计将具有更好的临床结果。随着新辅助化疗(NAC)联合靶向治疗时代的到来,HER2 阳性 BC 的 pCR 率显着提高,但其中约 50%的患者仍然对靶向治疗没有反应。肿瘤微环境(TME)的动态变化可能对 HER2 阳性 BC 的 pCR 结果产生关键影响。然而,目前还没有与治疗期间疗效相关的特异性免疫表型研究。我们对 28 例 HER2 阳性 BC 患者获得的 94 个 ROI 进行了全面的空间表达分析,包括他们的初始诊断阶段和术后状态。利用 DSP 技术,我们精确地绘制和量化了患者在这些关键时间点的 TME。值得注意的是,我们将标本分为四组:IM1、IM2、TM1 和 TM2。以 CD4⁺ 幼稚 T 细胞和幼稚 B 细胞为特征的 IM1 和 TM1 显示出较高的 pCR 率,而 IM2 和 TM2 表现出较低的率。此外,术后被归类为
  • 🔗 查看原文

4. Tetraspanin 13 通过促进 MHC-I 降解增强乳腺癌的免疫逃逸

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:免疫
  • 📝 描述:Secret hovertext: 与高免疫原性恶性肿瘤相比,乳腺癌通常具有“冷”肿瘤免疫微环境,其特征是免疫细胞浸润低和效应 T 细胞激活有限。这种免疫抑制表型对免疫检查点抑制剂和其他免疫治疗方法的疗效构成了重大障碍,凸显了确定限制抗肿瘤免疫机制的必要性。在这项研究中,我们确定了四跨蛋白 13 (TSPAN13) 在调节肿瘤细胞表面主要组织相容性复合物 I 类 (MHC-I) 表达中的作用,这是 CD8+ T 细胞识别肿瘤特异性抗原所必需的。在乳腺癌患者样本中,TSPAN13 表达与 CD8⁺ T 细胞浸润呈负相关。在机制上,TSPAN13 通过募集 STUB1 增强 MHC-I 的泛素化,从而促进溶酶体降解,显著降低细胞表面 MHC-I 水平。体外和体内实验都表明,肿瘤细胞中 TSPAN13 的丢失显着增强了 CD8+ T 细胞活性并改善了对肿瘤细胞的细胞毒性。此外,抑制 TSPAN13 表达显着增加了肿瘤对抗 PD-L1
  • 🔗 查看原文

5. 在造血 TET2 失活的情况下,对免疫检查点阻断的反应增强

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:免疫
  • 📝 描述:Secret hovertext: 使 TET2 失活的体细胞突变是克隆造血 (CH) 最常见的驱动因素之一。TET2 失活与单核细胞衍生炎症和改善嵌合抗原受体 T 细胞功能有关,表明它也可能影响免疫治疗反应。在这里,我们发现小鼠模型中的造血 Tet2 突变增强了免疫检查点阻断 (ICB) 反应,这需要吞噬细胞、CD4+ 和 CD8+ T 细胞的联合存在。随着骨髓或 T 细胞限制性 Tet2 失活或 20% Tet2 突变造血的小鼠,这种效果会消失。从机制上讲,在 Tet2 突变肿瘤浸润白细胞 (TIL) 中,ICB 优先限制与肿瘤进展相关的细胞状态,同时诱导抗肿瘤状态。Tet2 突变单核细胞激活共刺激程序,而 Tet2 突变 T 细胞表现出增强的 T 细胞记忆特征,同时减少疲惫和调节表型。临床上,结直肠癌和黑色素瘤患者的 TET2 驱动突变-CH(TET2-CH)的肿瘤表现出增强的免疫浸润、炎症和 T 细胞活化。在接受 ICB
  • 🔗 查看原文

6. 探索 EGFR 突变 NSCLC 中 EGFR TKI 耐药的前景 - 机制和不断发展的治疗方法。

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:耐药
  • 📝 描述:Secret hovertext: 对 EGFR 酪氨酸激酶抑制剂(TKIs)的耐药性仍然是 EGFR 突变非小细胞肺癌(NSCLC)临床治疗的主要障碍。尽管 EGFR TKI 的多次迭代具有变革性的治疗活性,从厄洛替尼和吉非替尼等第一代可逆抑制剂到目前标准护理的第三代共价抑制剂奥希替尼,但对这些药物的原发性或获得性耐药性不可避免地通过不同的机制出现。结合化疗、抗血管生成剂、双特异性抗体或抗体-药物偶联物的联合疗法的出现增加了临床获益,但引入了新的耐药表型,强调了治疗压力下肿瘤进化的动态可塑性和复杂性。在本综述中,我们全面综合了对第三代 EGFR TKIs 耐药的分子机制,描述了生物标志物引导和生物标志物非选择的治疗策略来克服这些机制,并讨论了通过早期应用联合疗法来预防耐药性的新方法。我们强调了治疗耐药性从放射学监测到分子监测的范式转变,并探讨了循环肿瘤 DNA 分析、人工智能和多组学的进步如何促进适应性治疗策略。随着治疗格
  • 🔗 查看原文

7. 癌症中的中性粒细胞细胞外陷阱

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:癌症
  • 📝 描述:Secret hovertext:
  • 🔗 查看原文
🧪 博客更新 (4条)

详细内容(全部4条)

1. CellWhisperer——多模态学习支持基于聊天方式的单细胞数据探索

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:single-cell
  • 📝 描述:CellWhisperer uses AI and RNA sequencing data to let researchers explore single-cell gene expression through natural-language chats, making complex biological data easier to understand and analyze…
  • 🔗 查看原文

2. 基于生物学、DNA/RNA 和人工智能的个性化癌症诊断结果,平均 10 天内即可交付。

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:cancer
  • 📝 描述:First Ascent Biomedical integrates functional drug testing, RNA sequencing, and AI to deliver personalized cancer treatment insights in just ten days, helping oncologists act before cancer progresses…
  • 🔗 查看原文

3. Wegovy 和 Ozempic 与癌症死亡率大幅下降有关

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:cancer
  • 📝 描述:GLP-1 drugs such as Ozempic and Wegovy may extend the lives of colon cancer patients, according to a major UC San Diego study. Patients on the medications had less than half the mortality rate of non-users. Researchers suspect the drugs’ anti-inflammatory and metabolic effects contribute to improved outcomes. They’re now calling for clinical trials to test whether these findings reflect a true anti-cancer mechanism.
  • 🔗 查看原文

4. 智能药物靶向癌细胞中隐藏的RNA弱点

  • ✍️ 作者:未知作者
  • 🏷️ 关键词:cancer
  • 📝 描述:Researchers have designed a smart drug that hunts down and breaks a little-known RNA that cancer cells depend on. The drug recognizes a unique fold in the RNA and triggers the cell to destroy it. Tests showed that removing this RNA slows cancer growth. The approach could lead to new treatments that attack cancer at its most fundamental level.
  • 🔗 查看原文

📊 关键词统计

关键词出现次数
免疫11
单细胞10
cancer10
生信9
肿瘤8
通路5
神经5
leukemia5
RNA-seq4
癌症4
resistance4
sequencing3
ChIP-seq3
空间组学3
methylation3
代谢2
基因组2
测序2
single-cell2
immune2

📎 更多内容

📰 公众号 其他内容 (28条)
🧬 数据前沿 其他内容 (25条)

📅 报告生成时间:2025-11-13 21:36
🤖 由 GitHub Actions 自动生成